Grant Sean, Chief Financial Officer of VERA Therapeutics (VERA), has demonstrated a clear selling bias in recent transactions, with no open-market purchases recorded in the latest filings. Since April 2024, Sean has executed 20 sales totaling approximately $4.9 million, dwarfing his $1.48 million in acquisition activity—all of which appears tied to option exercises rather than discretionary buying. The most concentrated selling occurred on April 3, 2024, when he disposed of shares across 18 separate transactions ranging from $2,979 to $2.8 million, with the latter representing the single largest liquidation. A subsequent sale on February 23, 2026, for $207,778 continued this divestment trend.
The transactions reveal a pattern of methodical unwinding, particularly notable given that all activity centers exclusively on VERA stock. While the April 2024 filings show Sean simultaneously exercised options to acquire shares (coded "M") for $1.48 million, these were immediately offset by substantially larger sales. The absence of any recent purchases—coupled with the scale and frequency of disposals—suggests a deliberate reduction in equity exposure. SEC records indicate no trades in other securities, focusing all liquidity events on his executive position at VERA.
AI-assisted summary